These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 230767)

  • 41. Feline oncornavirus-associated cell membrane antigen. III. Antibody titers in cats from leukemia cluster households.
    Essex M; Jakowski RM; Hardy WD; Cotter SM; Hess P; Sliski A
    J Natl Cancer Inst; 1975 Mar; 54(3):637-41. PubMed ID: 164563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative efficacy of the Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV vaccines against infection with circulating feline Calicivirus.
    Almeras T; Schreiber P; Fournel S; Martin V; Nicolas CS; Fontaine C; Lesbros C; Gueguen S
    BMC Vet Res; 2017 Oct; 13(1):300. PubMed ID: 29017551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and efficacy of a commercial feline leukemia virus vaccine.
    Pedersen NC
    J Vet Intern Med; 1993; 7(1):34-9. PubMed ID: 8384261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated.
    Hoover EA; Schaller JP; Mathes LE; Olsen RG
    Infect Immun; 1977 Apr; 16(1):54-9. PubMed ID: 194840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of an inactivated feline leukemia virus vaccine.
    Hoover EA; Mullins JI; Chu HJ; Wasmoen TL
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):379-83. PubMed ID: 8882314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus.
    Mathes LE; Olsen RG; Hebebrand LC; Hoover EA; Schaller JP; Adams PW; Nichols WS
    Cancer Res; 1979 Mar; 39(3):950-5. PubMed ID: 218725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of vaccination on parvovirus antigen testing in kittens.
    Patterson EV; Reese MJ; Tucker SJ; Dubovi EJ; Crawford PC; Levy JK
    J Am Vet Med Assoc; 2007 Feb; 230(3):359-63. PubMed ID: 17269866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural feline leukemia virus infection and the immune response of cats of different ages.
    Grant CK; Essex M; Gardner MB; Hardy WD
    Cancer Res; 1980 Mar; 40(3):823-9. PubMed ID: 6258787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Control of feline leukaemia virus.
    Weijer K; Uytdehaag FG; Osterhaus AD
    Vet Immunol Immunopathol; 1989 May; 21(1):69-83. PubMed ID: 2549695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hematologic abnormalities preceding apparent recovery from feline leukemia virus infection.
    Lester SJ; Searcy GP
    J Am Vet Med Assoc; 1981 Mar; 178(5):471-4. PubMed ID: 6263848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-SU Antibody Responses in Client-Owned Cats Following Vaccination against Feline Leukaemia Virus with Two Inactivated Whole-Virus Vaccines (Fel-O-Vax
    Westman M; Norris J; Malik R; Hofmann-Lehmann R; Parr YA; Armstrong E; McDonald M; Hall E; Sheehy P; Hosie MJ
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33546485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study.
    Lafrado LJ
    J Am Vet Med Assoc; 1994 Mar; 204(6):914-7. PubMed ID: 8188511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The kinetics of feline leukaemia virus shedding in experimentally infected cats are associated with infection outcome.
    Cattori V; Tandon R; Riond B; Pepin AC; Lutz H; Hofmann-Lehmann R
    Vet Microbiol; 2009 Jan; 133(3):292-6. PubMed ID: 18774240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feline leukemia virus immunity induced by whole inactivated virus vaccination.
    Torres AN; O'Halloran KP; Larson LJ; Schultz RD; Hoover EA
    Vet Immunol Immunopathol; 2010 Mar; 134(1-2):122-31. PubMed ID: 20004483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo infection of marrow stromal fibroblasts by feline leukemia virus.
    Linenberger ML; Abkowitz JL
    Exp Hematol; 1992 Sep; 20(8):1022-7. PubMed ID: 1324184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-time PCR investigation of feline leukemia virus proviral and viral RNA loads in leukocyte subsets.
    Cattori V; Pepin AC; Tandon R; Riond B; Meli ML; Willi B; Lutz H; Hofmann-Lehmann R
    Vet Immunol Immunopathol; 2008 May; 123(1-2):124-8. PubMed ID: 18304650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Shedding of feline leukemia virus RNA in saliva is a consistent feature in viremic cats.
    Gomes-Keller MA; Tandon R; Gönczi E; Meli ML; Hofmann-Lehmann R; Lutz H
    Vet Microbiol; 2006 Jan; 112(1):11-21. PubMed ID: 16303261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a genetically engineered vaccine against feline leukemia virus infection.
    Kensil CR; Barrett C; Kushner N; Beltz G; Storey J; Patel U; Recchia J; Aubert A; Marciani D
    J Am Vet Med Assoc; 1991 Nov; 199(10):1423-7. PubMed ID: 1666096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of feline leukemia virus subgroup A infection by coinoculation with subgroup B.
    Phipps AJ; Hayes KA; Al-dubaib M; Roy-Burman P; Mathes LE
    Virology; 2000 Nov; 277(1):40-7. PubMed ID: 11062034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A vector expressing feline mature IL-18 fused to IL-1beta antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus.
    O'Donovan LH; McMonagle EL; Taylor S; Bain D; Pacitti AM; Golder MC; McDonald M; Hanlon L; Onions DE; Argyle DJ; Jarrett O; Nicolson L
    Vaccine; 2005 May; 23(29):3814-23. PubMed ID: 15893619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.